How to buy Tenax Therapeutics stock (TENX)

Tenax Therapeutics is a biotechnology business based in the US. Tenax Therapeutics shares (TENX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.65 – an increase of 2.36% over the previous week. Tenax Therapeutics employs 5 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Tenax Therapeutics stock

Buy Tenax Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Tenax Therapeutics stock price (NASDAQ: TENX)

Use our graph to track the performance of TENX stocks over time.

Tenax Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.65
52-week range	$2.77 - $27.33
50-day moving average more info button	$4.82
200-day moving average more info button	$3.92
Wall St. target price	$16.30
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-13.05

Is it a good time to buy Tenax Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tenax Therapeutics price performance over time

Historical closes compared with the close of $5.49 from 2024-12-23

1 week (2024-12-17)	-5.51%
1 month (2024-11-25)	8.50%
3 months (2024-09-24)	61.00%
6 months (2024-06-24)	81.79%

1 year (2023-12-22)	1,676.70%
2 years (2022-12-23)	-97.02%
3 years (2021-12-23)	1792
5 years (2019-12-24)	1872

Tenax Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-66.09%
Return on equity TTM	-113.79%
Profit margin	0%
Book value	$27.15
Market Capitalization more info button	$18.8 million

TTM: trailing 12 months

Tenax Therapeutics share dividends

We're not expecting Tenax Therapeutics to pay a dividend over the next 12 months.

Have Tenax Therapeutics's shares ever split?

Tenax Therapeutics's shares were split on a 1:80 basis on 2 January 2024 . So if you had owned 80 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tenax Therapeutics shares – just the quantity. However, indirectly, the new 7900% higher share price could have impacted the market appetite for Tenax Therapeutics shares which in turn could have impacted Tenax Therapeutics's share price.

Tenax Therapeutics share price volatility

Over the last 12 months, Tenax Therapeutics's shares have ranged in value from as little as $2.77 up to $27.328. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tenax Therapeutics's is 2.154. This would suggest that Tenax Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Tenax Therapeutics overview

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc.

Frequently asked questions

What percentage of Tenax Therapeutics is owned by insiders or institutions?
Currently 0.326% of Tenax Therapeutics shares are held by insiders and 47.95% by institutions. How many people work for Tenax Therapeutics?
Latest data suggests 5 work at Tenax Therapeutics. When does the fiscal year end for Tenax Therapeutics?
Tenax Therapeutics's fiscal year ends in December. Where is Tenax Therapeutics based?
Tenax Therapeutics's address is: 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 What is Tenax Therapeutics's ISIN number?
Tenax Therapeutics's international securities identification number is: US88032L2097 What is Tenax Therapeutics's CUSIP number?
Tenax Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69207P100